"Long-term collaboration with a global biopharma company will generate around 200 new jobs in the Visp biopark with operations expected to start from end-2022," Lonza said in a statement.
(Reporting by John Miller; editing by Thomas Seythal)
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
522.4 CHF | +1.67% | +4.22% | +48.15% |
Apr. 18 | Global markets live: DocMorris, Microsoft, Oracle, Micron, Netflix... | |
Apr. 18 | Lonza Finance Launches EUR1 Billion 12-Year Euro Bond | DJ |
ZURICH (Reuters) - Lonza on Wednesday announced a deal with an unspecified customer for two new facilities for commercialization of antibody-drug conjugates at its Visp, Switzerland, site as the contract drug maker expands its work with the technology.
"Long-term collaboration with a global biopharma company will generate around 200 new jobs in the Visp biopark with operations expected to start from end-2022," Lonza said in a statement.
(Reporting by John Miller; editing by Thomas Seythal)
1st Jan change | Capi. | |
---|---|---|
+48.15% | 40.57B | |
+1.12% | 42.59B | |
+6.77% | 40.65B | |
-11.96% | 26.77B | |
+6.01% | 24.81B | |
-24.92% | 18.17B | |
+27.16% | 12.05B | |
-3.63% | 11.7B | |
+7.30% | 11.1B | |
-18.79% | 9.85B |